Skandinaviska Enskilda Banken AB publ Grows Stock Holdings in Edwards Lifesciences Co. (NYSE:EW)

Skandinaviska Enskilda Banken AB publ increased its stake in shares of Edwards Lifesciences Co. (NYSE:EW - Free Report) by 6.3% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 949,074 shares of the medical research company's stock after buying an additional 56,051 shares during the period. Skandinaviska Enskilda Banken AB publ owned about 0.16% of Edwards Lifesciences worth $70,459,000 as of its most recent SEC filing.

Other hedge funds have also added to or reduced their stakes in the company. Versor Investments LP increased its holdings in Edwards Lifesciences by 102.5% in the 3rd quarter. Versor Investments LP now owns 4,455 shares of the medical research company's stock worth $294,000 after acquiring an additional 2,255 shares during the last quarter. Entropy Technologies LP bought a new stake in shares of Edwards Lifesciences in the third quarter valued at approximately $2,069,000. GSA Capital Partners LLP purchased a new stake in shares of Edwards Lifesciences during the 3rd quarter valued at approximately $481,000. Future Fund LLC boosted its holdings in Edwards Lifesciences by 37.8% in the 3rd quarter. Future Fund LLC now owns 15,898 shares of the medical research company's stock worth $1,074,000 after buying an additional 4,363 shares during the period. Finally, Empower Advisory Group LLC grew its stake in Edwards Lifesciences by 25.8% in the 3rd quarter. Empower Advisory Group LLC now owns 705,878 shares of the medical research company's stock valued at $46,581,000 after buying an additional 144,857 shares in the last quarter. Institutional investors own 79.46% of the company's stock.

Analyst Ratings Changes

A number of analysts recently weighed in on the stock. Royal Bank of Canada reaffirmed an "outperform" rating and set a $85.00 target price on shares of Edwards Lifesciences in a report on Wednesday, February 12th. Stifel Nicolaus raised shares of Edwards Lifesciences from a "hold" rating to a "buy" rating and upped their price target for the stock from $75.00 to $90.00 in a report on Thursday, January 30th. Truist Financial restated a "hold" rating and set a $78.00 target price (up from $70.00) on shares of Edwards Lifesciences in a research report on Thursday, December 5th. Canaccord Genuity Group raised their price target on Edwards Lifesciences from $68.00 to $71.00 and gave the company a "hold" rating in a report on Thursday, February 13th. Finally, The Goldman Sachs Group boosted their price objective on Edwards Lifesciences from $81.00 to $90.00 and gave the stock a "buy" rating in a report on Thursday, December 5th. One equities research analyst has rated the stock with a sell rating, fourteen have given a hold rating and twelve have assigned a buy rating to the company's stock. According to data from MarketBeat.com, Edwards Lifesciences has an average rating of "Hold" and a consensus price target of $79.95.

Remove Ads

Edwards Lifesciences Stock Up 2.0 %

EW stock traded up $1.38 on Monday, reaching $70.67. 5,653,039 shares of the company traded hands, compared to its average volume of 4,585,872. The firm has a fifty day simple moving average of $71.74 and a 200-day simple moving average of $70.34. The company has a market cap of $41.55 billion, a P/E ratio of 10.14, a price-to-earnings-growth ratio of 4.82 and a beta of 1.12. Edwards Lifesciences Co. has a one year low of $58.93 and a one year high of $96.12. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89.

Edwards Lifesciences (NYSE:EW - Get Free Report) last released its quarterly earnings data on Tuesday, February 11th. The medical research company reported $0.59 earnings per share for the quarter, beating analysts' consensus estimates of $0.55 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. Research analysts anticipate that Edwards Lifesciences Co. will post 2.45 earnings per share for the current year.

Insiders Place Their Bets

In other news, VP Daniel J. Lippis sold 500 shares of the stock in a transaction that occurred on Thursday, January 16th. The shares were sold at an average price of $68.76, for a total value of $34,380.00. Following the transaction, the vice president now owns 23,189 shares in the company, valued at $1,594,475.64. This represents a 2.11 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, VP Donald E. Bobo, Jr. sold 9,500 shares of the business's stock in a transaction that occurred on Thursday, March 13th. The shares were sold at an average price of $67.96, for a total transaction of $645,620.00. Following the sale, the vice president now owns 46,936 shares of the company's stock, valued at $3,189,770.56. This trade represents a 16.83 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 51,303 shares of company stock valued at $3,715,776. 1.29% of the stock is owned by insiders.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.